Please login to the form below

Not currently logged in

CureVac expands COVID-19 vaccine trial protocol to include variant specification

Company is aiming to ensure its vaccine efficacy data is 'meaningful' against new virus variants

German biotech company CureVac is planning to expand the protocols for its ongoing late-stage trials of its COVID-19 vaccine candidate CVnCoV to determine if the jab is effective against new virus variants.

The CVnCoV vaccine candidate is currently being evaluated in the HERALD phase 2b/3 trial in Europe and Latin America.

Due to the rapid emergence of new virus variants in the countries where the study is being conducted, CureVac has identified the need for further analysis specification for the anticipated case-driven interim analysis.

This will allow CureVac to determine the efficacy of the vaccine candidate against select variants, the company said in a statement.

CureVac is in ongoing discussions with the European Medicines Agency (EMA) to potentially include an amendment to the study related to select virus strains.

In addition, for the company’s phase 2a dose-confirmation trial in older adults in Peru and Panama, CureVac has now submitted a protocol amendment to include a secondary objective for vaccine efficacy.

Initially, the study aimed to evaluate safety, reactogenicity and immunogenicity of CvnCoV in adult participants.

“The additional efficacy analysis in phase 2a is intended to leverage the data we can collect from older adults, and will represent important complementary data to the statistically relevant efficacy data from our HERALD trial,” said Ulrike Gnad-Vogt, interim chief development officer of CureVac.

“At the same time we need to make sure that our efficacy data is meaningful in view of the emergence of new virus variants. We are therefore aiming to specify what type of virus we are dealing with in the HERALD trial,” he added.

Data from both clinical trials is expected in the second quarter of 2021, which reaffirms CureVac’s plan to file for formal marketing authorisation within the second quarter of the year.

The EMA’s Committee for Medicinal Products for Human Use (CHMP) started its rolling review of CVnCoV in February.

In November 2020, CureVac revealed early data for its investigational COVID-19 vaccine showing that the jab triggered an immune response in participants in a phase 1 study.

The mRNA-based vaccine candidate also induced strong binding and neutralising antibody responses in the early study, according to CureVac.

Article by
Lucy Parsons

23rd March 2021

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company
Aurora Healthcare Communications

We're a leading healthcare strategic communications agency helping pharmaceutical companies adapt fast to improve the lives of patients and healthcare...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....